Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors

Bone Marrow Transplantation

Volumn 22, Issue 3, 1998, Pages 265-271

  Lancet, J E ^a   Rapoport, A P ^a,c   Brasacchio, R ^a   Eberly, S ^a   Raubertas, R F ^a   Linder, T ^a   Muhs, A ^a   Duerst, R E ^a   Abboud, C N ^a   Packman, C H ^a   Dipersio, J F ^b   Constine, L S ^a   Rowe, J M ^a   Liesveld, J L ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Autotransplantation; High dose chemotherapy; Hodgkin's disease; Prognostic factors; Radiotherapy

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER SURVIVAL; CARDIOTOXICITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RELAPSE; SURVIVAL;

EID: 0031857595     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701325     Document Type: Article

References (33)

1. Longo DL, Duffey PL, Young RC et al. Conventionaldose combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
2. Burns LJ, Daniels KA, McGlave PB et al. Autologous transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. Bone Marrow Transplant 1995; 16: 13-18.
3. Chopra R, McMillan AK, Linch DC et al. The place of highdose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
4. Jones RJ, Piantadosi S, Mann RB et al. High-dose cytotoxic therapy and bone marrow transplantation relapsed Hodgkin's disease. J Clin Oncol 1990; 8: 527-537.
5. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704-711.
6. Schmitz N, Glass B, Dreger P et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hetnatol 1993; 66: 251-256.
7. Nademanee A, O'Donnell MR, Synder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-390.
8. Reece DE, Phillips GL. Intensive therapy and autotransplantation in Hodgkin's disease. Stem Cells 1994; 12: 477-493.
9. Bolwell BJ. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphorria. Semin Oncol 1994; 21: 86-95.
10. Harding M, Selby P, Gore M et al. High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. Eur J Cancer 1992; 28A: 1396-1400.
11. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
12. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
13. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-c and dexamethasone (DHAP). Blood 1988; 71: 117-122.
14. Rapoport AP, Rowe JM, Heal JM et al. Treatment of relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma with high-dose chemotherapy followed by unstimulated autologous peripheral stem cell rescue. Am J Hematol 1992; 40: 86-92.
15. Abboud CN, Liesveld JL, Belanger TJ et al. Prospective randomized trial (NCI/T92-0010), comparing the efficacy of hematopoietic growth factors, for mobilizing peripheral blood stem cells in autologous bone marrow transplantation: II Progenitor mobilization kinetics. Blood 1995; 86: S1 (Abstr.).
16. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall: London, 1984.
17. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: result of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
18. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
19. Jochelson M, Tarbell NJ, Freedman AS et al. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 6: 329-331.
20. Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation - a report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
21. van Besien K, Tabocoff J, Rodeiguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate-grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995; 15: 549-555.
22. Takvorian T, Parker LM, Hochberg FH et al. Autologous bone marrow transplantation: host effects of high-dose BCNU. J Clin Oncol 1983; 1: 610-620.
23. Ager S, Mahendra P, Richards EM et al. High-dose carmustine, etoposide and melphalan ('BEM'). Autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996; 17: 335-340.
24. Sont JK, van Stiphout WAJH, Noordijk EM et al. Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 1992; 65: 213-218.
25. Doria R, Holford T, Farber LR et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016-2022.
26. Fetscher S, Finke J, Engelhardt R, Mertelsmann R. Earlyonset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol 1997; 74: 73-77.
27. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
28. Crowley KS, Don G, Gibson GE et al. Primary gastrointestinal tract lymphoma - a clinicopathological study of 28 cases. Aust NZ J Med 1982; 12: 135-142.
29. Pezner RD, Nademanee A, Niland JC et al. Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 1995; 34: 23-29.
30. Mundt AJ, Sibley G, Williams S et at. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved-field radiotherapy for relapsed/refractory Hodgkin's disease. Inl J Radiat Oncol Biol Phys 1995; 33: 261-270.
31. Poen JC, Hoppe RT, Horning SJ et al. High-dose therapy and autologous bone marrow transplantation for relapsed/ refractory Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1996; 36: 3-12.
32. Leigh BR, Fox KA, Mack CF et al. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Int J Radial Oncol Biol Phys 1993; 27: 855-862.
33. Fabian CJ, Mansfield CM, Dahlberg S et al. Low-dose involved-field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 1994; 120: 903-912.